Effect of medroxyprogesterone acetate on serum levels of LH, FSH, cortisol, and estrone in patients with endometrial carcinoma
- 1 May 1981
- journal article
- research article
- Published by Springer Nature in Archiv für Gynäkologie
- Vol. 230 (3) , 205-211
- https://doi.org/10.1007/bf02111804
Abstract
Medroxyprogesterone acetate (MPA) was administered orally for at least 6 months to 25 patients with endometrial adenocarcinoma starting 1 week after hysterectomy and bilateral ovariectomy. We measured serum concentrations of MPA during treatment and serum levels of LH, FSH, cortisol, and estrone before and during treatment with MPA. The serum levels of MPA 3–5 h after ingestion of a daily 100-mg dose of MPA at 08.00 h, varied considerably, the mean value (± SE) being 43 ± 3.6 nmol/l range 15–119 nmol/l. Serum FSH levels rose after operation in the five premenopausal patients and remained elevated despite MPA treatment. In the 20 postmenopausal patients, however, initially high serum FSH and LH levels declined to half the starting values as a result of MPA treatment. After the administration of MPA for 6 months the mean serum cortisol and estrone concentrations at 08.00 a.m. had fallen to 78% and 82% of the mean values before treatment.This publication has 14 references indexed in Scilit:
- Female sex steroid receptors in normal, hyperplastic and carcinomatous endometrium. The relationship to serum steroid hormones and gonadotropins and changes during medroxyprogesterone acetate administrationInternational Journal of Cancer, 1979
- Surgical treatment of Stages IB and IIA invasive carcinoma of the cervix by radical abdominal hysterectomyAmerican Journal of Obstetrics and Gynecology, 1979
- In VivoMetabolism of Progestins. V. The Effect of Protocol Design on the Estimated Metabolic Clearance Rate and Volume of Distribution of Medroxyprogesterone Acetate in Women*Journal of Clinical Endocrinology & Metabolism, 1979
- Serum Levels of Total Dehydroepiandrosterone and Total Estrone in Postmenopausal Women with Special Regard to Carcinoma of the Uterine CorpusActa Obstetricia et Gynecologica Scandinavica, 1979
- Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinomaActa Obstetricia et Gynecologica Scandinavica, 1979
- Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancerAmerican Journal of Obstetrics and Gynecology, 1978
- Medroxyprogesterone acetate, estradiol, FSH and LH in peripheral blood after intramuscular administration of depo-provera® to womenContraception, 1976
- The Effect of Medroxyprogesterone Acetate on the Pituitary-Adrenal AxisJournal of Clinical Endocrinology & Metabolism, 1976
- Effect of Medroxyprogesterone Acetate (Provera) on the Metabolism and Biological Activity of TestosteroneJournal of Clinical Endocrinology & Metabolism, 1970
- Management of advanced endometrial adenocarcinoma with medroxyprogesterone acetateAmerican Journal of Obstetrics and Gynecology, 1965